VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COSTEM 2021 | Early allogeneic transplantation for myelofibrosis patients responding to ruxolitinib

Juan Carlos Hernández-Boluda, MD, PhD, Hospital Clínico Universitario Valencia, Valencia, Spain, discusses the role of early allogeneic transplantation for patients with primary myelofibrosis who respond to JAK2 inhibition. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.

Disclosures

Juan Carlos Hernández-Boluda, MD, PhD, has received advisory honoraria from BMS and AOP Pharma; travel support from Incyte and Pfizer; and speaker fees from Pfizer, Novartis and Incyte.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter